A new dietary therapy using resistant starch for managing Type 1 diabetes
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes
This study is exploring a new way to help teenagers with Type 1 diabetes by using a special type of dietary fiber that might improve their gut health and blood sugar control, aiming to make living with diabetes a bit easier and better overall.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project ID | NIH-10906121 on NIH RePORTER |
What this research studies
This research investigates a novel therapy using modified resistant starch to improve management of Type 1 diabetes (T1D) in adolescents. The approach focuses on how dietary fiber, specifically high amylose starch, can positively influence the gut microbiome and immune response, potentially leading to better glycemic control and overall quality of life. By examining the effects of this dietary intervention, the study aims to provide a new strategy for T1D management that goes beyond insulin therapy. Participants will be monitored for changes in their gut microbiota and related health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents under 16 years of age diagnosed with Type 1 diabetes.
Not a fit: Patients over the age of 16 or those with other forms of diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new dietary treatment option that improves glycemic control and quality of life for adolescents with Type 1 diabetes.
How similar studies have performed: Previous studies have shown promising results with dietary interventions like fecal microbiome therapy and probiotics in managing Type 1 diabetes, suggesting that this approach may also be effective.
Where this research is happening
Rockville, UNITED STATES
- Rise Therapeutics, LLC — Rockville, United States (Active)
Researchers
- Principal investigator: Furlan Freguia, Christian — Rise Therapeutics, LLC
- Study coordinator: Furlan Freguia, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.